Financial Trade Freedom - Investing and Stock News
  • Investing
  • News
  • Editor’s Pick
  • Economy
  • Stock
  • Investing
  • News
  • Editor’s Pick
  • Economy
  • Stock
No Result
View All Result
Financial Trade Freedom - Investing and Stock News
No Result
View All Result
Home Stock

Novo Nordisk stock posts worst week since 2021, but analysts see a bigger problem ahead

admin by admin
August 1, 2025
in Stock
0
Novo Nordisk stock posts worst week since 2021, but analysts see a bigger problem ahead
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Novo Nordisk stock sharply tanked this week, marking the pharmaceutical company’s worst-ever weekly loss with a decline of more than 30% by Friday.

This plunge extended the stock to its lowest point since August 2021, erasing nearly all gains made since the launch of its blockbuster weight-loss drug Wegovy.

Not long ago, the company was riding high, thanks to the massive success of drugs like Wegovy and Ozempic.

But now, it’s staring down a tough road. Sales projections have taken a hit, competitors are closing in, and US regulators are turning up the heat.

The sudden turn of events has rattled investors and sparked serious concerns about whether the company can hold onto its lead in an industry that’s changing fast.

Novo Nordisk stock: What’s behind the sharp drop?

On July 29, the company announced a significant revision to its full-year 2025 sales growth outlook, lowering the projected range from 13–21% to 8–14%.

Profit expectations took a hit, too. Operating income growth was revised down from 16–24% to a new range of just 10–16%.

The downgrade followed disappointing sales figures for its flagship drugs, Ozempic and Wegovy, which are increasingly feeling the pressure from growing competition, particularly in the US market.

Novo Nordisk is also struggling against growing competition from compounded or generic versions of Wegovy and competing GLP-1 drugs like Eli Lilly’s products.

The persistent use of unsafe compounded GLP-1s and counterfeit semaglutide products in the US is undermining Wegovy’s uptake.

Additionally, slower market expansion and tougher reimbursement scenarios have dampened sales growth.

These factors point to a recalibration of the obesity medication market and heightened challenges within the US, Novo Nordisk’s largest market.

Investors were already on edge when Novo Nordisk announced Maziar Mike Doustdar would take over as CEO on August 7, 2025, and the timing couldn’t have been worse.

His appointment came on the heels of a sharp cut in the company’s sales forecast, amplifying concerns and sending the stock even lower.

The leadership change follows the earlier departure of former CEO Lars Fruergaard Jørgensen, who was pushed out as doubts grew over the company’s ability to stay ahead in an increasingly competitive and fast-moving market.

What analysts say?

Analysts have a cautious view on Novo Nordisk’s stock following the company’s recent sales forecast cut and leadership change.

Bank of America downgraded the stock to “Neutral,” citing an “uncertain path to recovery for Wegovy and Ozempic” and growth headwinds from patent expiries, US pricing pressures, and competition from Eli Lilly’s drugs. 

Nordnet analysts pointed to investor panic over potential further downgrades amid US market challenges and political pressure on drug prices. 

MarketBeat data shows a consensus rating around “Hold,” with a target price near $93.67. Of 19 analysts tracked, seven recommend strong buy, nine hold, and one moderate sell.

The post Novo Nordisk stock posts worst week since 2021, but analysts see a bigger problem ahead appeared first on Invezz


Previous Post

Private equity giants accelerate push into UK pension risk-transfer market

Next Post

OpenAI raises $8.3B as AI demand grows: report

Next Post
OpenAI raises $8.3B as AI demand grows: report

OpenAI raises $8.3B as AI demand grows: report

  • Trending
  • Comments
  • Latest
U.S. homebuilders raise alarm over tariffs as sentiment falls to 5-month low

U.S. homebuilders raise alarm over tariffs as sentiment falls to 5-month low

February 19, 2025
How Companies Use Derivatives To Hedge Risk

How Companies Use Derivatives To Hedge Risk

February 19, 2025
As Joann Fabrics and JCPenney announce store closings, here’s what’s driving the pattern

As Joann Fabrics and JCPenney announce store closings, here’s what’s driving the pattern

February 17, 2025
KFC moves U.S. headquarters from Kentucky to Texas

KFC moves U.S. headquarters from Kentucky to Texas

February 19, 2025
Why Friday’s sell-off in S&P 500 was not surprising and what comes next

Why Friday’s sell-off in S&P 500 was not surprising and what comes next

0
From tariffs to DOGE, what companies are saying about the impact of MAGA policies

From tariffs to DOGE, what companies are saying about the impact of MAGA policies

0
Tesla’s law firm drafts Delaware bill that could salvage Musk pay package

Tesla’s law firm drafts Delaware bill that could salvage Musk pay package

0
Coca-Cola takes on Olipop and Poppi with new prebiotic soda brand, Simply Pop

Coca-Cola takes on Olipop and Poppi with new prebiotic soda brand, Simply Pop

0
Why Friday’s sell-off in S&P 500 was not surprising and what comes next

Why Friday’s sell-off in S&P 500 was not surprising and what comes next

August 2, 2025
Retail investors shift focus to Europe as US valuations stretch

Retail investors shift focus to Europe as US valuations stretch

August 2, 2025
Berkshire Hathaway posts 4% dip in Q2 operating profit, writes down Kraft Heinz stake

Berkshire Hathaway posts 4% dip in Q2 operating profit, writes down Kraft Heinz stake

August 2, 2025
Bank of America picks 5 stocks with post earnings rally potential

Bank of America picks 5 stocks with post earnings rally potential

August 2, 2025

    Get Smarter with Your Money – Sign Up for Free Financial Tips!


    Join our community of savvy savers and investors! By signing up, you'll receive weekly emails packed with personalized financial tips, budgeting hacks, and investment strategies tailored to your income level. Take control of your finances today – it’s free and only takes a minute!

    Recent News

    Why Friday’s sell-off in S&P 500 was not surprising and what comes next

    Why Friday’s sell-off in S&P 500 was not surprising and what comes next

    August 2, 2025
    Retail investors shift focus to Europe as US valuations stretch

    Retail investors shift focus to Europe as US valuations stretch

    August 2, 2025
    Berkshire Hathaway posts 4% dip in Q2 operating profit, writes down Kraft Heinz stake

    Berkshire Hathaway posts 4% dip in Q2 operating profit, writes down Kraft Heinz stake

    August 2, 2025
    Bank of America picks 5 stocks with post earnings rally potential

    Bank of America picks 5 stocks with post earnings rally potential

    August 2, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Disclaimer: FinancialTradeFreedom.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 financialtradefreedom.com | All Rights Reserved

    No Result
    View All Result
    • About us
    • Contacts
    • Email Whitelisting
    • Investing and Stock News
    • Privacy Policy
    • Terms and Conditions
    • Thank you

    Disclaimer: FinancialTradeFreedom.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 financialtradefreedom.com | All Rights Reserved